Skip navigation

Calls to Action

autism research

DELSIA’s First Award funded by Autism Speaks Supports Development of Arbaclofen and other Innovative Treatments for ASD

Autism Speaks and Delivering Scientific Innovation for Autism, LLC (DELSIA), its non-profit affiliate, announced today a partnership be

December 03, 2012

New York, N.Y. (December 3, 2012) – Autism Speaks and Delivering Scientific Innovation for Autism, LLC (DELSIA), its non-profit affiliate, announced today a partnership between DELSIA and Seaside Therapeutics (Cambridge, Mass.) that aims to discover biomarkers that can be used to facilitate the development of safe, effective and personalized treatments of autism spectrum disorders (ASD).

A large clinical trial will test the safety and effectiveness of oxytocin nasal spray to improve sociability and communication in children and teens with autism. The federally funded clinical trial follows the promising results of a pilot study funded by Autism Speaks.

High-Priority Research Will Study the Impact of the Proposed DSM-5 on Autism Diagnosis; a Suzanne and Bob Wright Trailblazer Grant Will Track Prenatal and Postnatal Chemical Exposures; and Studies Will Lead to Development of Medicines, New Behavioral Treatments, and Improve Minority Community Access to Early Intervention

Autism Speaks announced the award of new research grants totaling nearly $2.9 million in funding to support autism research. “

June 21, 2012

New York, N.Y. (June 21, 2012) – Autism Speaks, the world’s leading autism science and advocacy organization, today announced the award of new research grants totaling nearly $2.9 million in funding to support autism research.